Genmab became a publicly traded company in 2000. Genmab’s ordinary shares are listed on Nasdaq Copenhagen under the symbol GMAB, and it is a member of the OMX Nordic Large Cap Index, the OMX Copenhagen Benchmark Index and the OMX Copenhagen 25 Index (OMXC25). Genmab’s ID code/ISIN is DK0010272202. In July 2019, Genmab’s American Depositary Shares issued pursuant to its ADR program were also listed in the United States on the Nasdaq Global Select Market under the symbol GMAB and are part of the NASDAQ Biotechnology Index (Nasdaq: NBI).
Genmab has approximately 64,000 registered shareholders. There are 65,211,003 shares outstanding. Each share has a nominal value of DKK 1, resulting in a share capital of DKK 65,211,003.
Genmab is headquartered in Copenhagen, Denmark and its main research activities are in Utrecht, the Netherlands. Genmab has development and administrative teams in both Copenhagen, Denmark and Princeton, NJ, USA and a regional office in Japan.
Genmab has four subsidiaries: Genmab B.V. and Genmab Holding B.V. in the Netherlands, Genmab US, Inc. in the United States and Genmab K.K. in Japan.
On December 31, 2019 Genmab had 548 full time employees.
Genmab develops antibody therapeutics. Genmab's main focus is on products that can be used to treat cancer. To read more about the company's products in clinical development please go to the Products in development page.
There are three Genmab-created products that have received regulatory approval: DARZALEX® (daratumumab), Arzerra® (ofatumumab) and TEPEZZA™ (teprotumumab-trbw). Read more about these products on our Products in development page.
Yes, Genmab has a number of products in clinical and pre-clinical development. Refer to our product pipeline for more information.
You can find our interim financial reports and annual reports in the Financial reports section of this website.
- Our proprietary DuoBody® technology platform enables us to create human bispecific antibodies that bind to two different targets.
- Genmab’s novel proprietary HexaBody® platform is designed to increase the potency of antibodies. The technology has the potential to enhance antibody therapeutics for a broad range of applications in cancer and infectious diseases.
- Antibody Drug Conjugate (ADC) technology, licensed from other companies, combines antibodies with cytotoxic agents to selectively target tumor cells.
- Antibody generation technology platforms such as the OmniAb® transgenic mouse and rat platforms and the UltiMAb® transgenic mouse technology are used to create antibodies.
PricewaterhouseCoopers is Genmab's auditor.
For Media and Investor Relations please contact:
Corporate Vice President, Communications & Investor Relations
Telephone: +1 609 524 0065
For Investor Relations please contact:
Senior Director, Investor Relations
Telephone: +45 3377 9558
Yes, Genmab has established a sponsored Level 3 ADR program. American Depositary Shares issued under the ADR Program are listed on the Nasdaq Global Select Market in the United States under the symbol GMAB. Click here for more information.